Regeneron’s COVID-19 Antibody Cocktail Shows Early Promise, But Does It Merit An EUA?

Could Help Patients Who Lack Own Antibody Response

Data from the first 275 patients in the trial are promising, but outside experts say they are wary of another hasty Emergency Use Authorization. 

Covid test
Serology tests found around 40% of trial patients had generated no antibodies against the disease - making them higher risk, and more likely to benefit from REGN-COV2.

Early data from Regeneron Pharmaceuticals, Inc.’s REGN-COV2 shows the antibody cocktail has promise in treating non-hospitalized COVID-19 patients, with the most significant results in individuals who have not mounted an antibody response against the infection.

The first data from a descriptive analysis of the first 275 patients treated in a seamless Phase I/II/III trial showed...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip